Elmind Capital LP Buys New Shares in Amylyx Pharmaceuticals, Inc. $AMLX

Elmind Capital LP bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 112,000 shares of the company’s stock, valued at approximately $1,353,000. Elmind Capital LP owned about 0.10% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of AMLX. Millennium Management LLC increased its position in shares of Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after acquiring an additional 2,487,617 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Amylyx Pharmaceuticals by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock valued at $7,090,000 after acquiring an additional 143,065 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Amylyx Pharmaceuticals by 62.7% in the second quarter. JPMorgan Chase & Co. now owns 87,989 shares of the company’s stock valued at $564,000 after acquiring an additional 33,920 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $47,000. Finally, Rhumbline Advisers acquired a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $645,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Bank of America lifted their target price on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Mizuho lifted their price target on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price target on the stock. Guggenheim boosted their price target on Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Amylyx Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ AMLX opened at $15.25 on Thursday. The business’s 50 day moving average price is $15.15 and its two-hundred day moving average price is $14.27. The company has a market cap of $1.70 billion, a PE ratio of -10.17 and a beta of -0.16. Amylyx Pharmaceuticals, Inc. has a twelve month low of $4.80 and a twelve month high of $18.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.4 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.